 |
88 Diseases |  |
13 Trials |
|
13 Trials |  |
791 News |  |
| «123456789101112» |
- ||||||| Epogen (epoetin alfa) / Amgen
Trial completion: A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin (clinicaltrials.gov) - Apr 8, 2014
P3, N=320, Completed, Sponsor: Hospira, Inc.
Active, not recruiting --> Completed
- ||||||| Epogen (epoetin alfa) / Amgen
Trial completion: AiME - 01: A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin (clinicaltrials.gov) - Apr 8, 2014
P3, N=612, Completed, Sponsor: Hospira, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Epogen (epoetin alfa) / Amgen, Venofer (iron sucrose complex) / Daiichi Sankyo
Trial termination: The Effect of Epogen and Venofer Dosing Management on Hemoglobin Stability (clinicaltrials.gov) - Mar 20, 2014
P4, N=48, Terminated, Sponsor: Michael Germain
Active, not recruiting --> Completed Recruiting --> Terminated; Study has been terminated due to lack of financial support
- Epogen (epoetin alfa) / Amgen, Venofer (iron sucrose complex) / Daiichi Sankyo
Enrollment change: The Effect of Epogen and Venofer Dosing Management on Hemoglobin Stability (clinicaltrials.gov) - Mar 20, 2014
P4, N=48, Terminated, Sponsor: Michael Germain
Recruiting --> Terminated; Study has been terminated due to lack of financial support N=200 --> 48
- ||| Evrenzo (roxadustat) / FibroGen
Enrollment change: Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis (clinicaltrials.gov) - Mar 17, 2014
P2, N=161, Completed, Sponsor: FibroGen
N=200 --> 48 N=214 --> 161
- |||| Evrenzo (roxadustat) / FibroGen
Trial completion: Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis (clinicaltrials.gov) - Mar 17, 2014
P2, N=161, Completed, Sponsor: FibroGen
N=214 --> 161 Active, not recruiting --> Completed
- ||||||| Epogen (epoetin alfa) / Amgen, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Surgery: SWOG-CAN-NCIC-MA21: Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer (clinicaltrials.gov) - Mar 16, 2014
P3, N=2104, Completed, Sponsor: NCIC Clinical Trials Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Epogen (epoetin alfa) / Amgen
New P2 trial: OETNA: Optimized Erythropoietin (EPO) Treatment (clinicaltrials.gov) - Feb 27, 2014
P2, N=62, Not yet recruiting, Sponsor: University of Iowa
- Epogen (epoetin alfa) / Amgen
Trial termination, Post-transplantation: Study of Epoetin Alfa to Treat Anemia After Kidney Transplantation (clinicaltrials.gov) - Feb 25, 2014
P=N/A, N=100, Terminated, Sponsor: Mehrotra, Anita, M.D.
Active, not recruiting --> Completed Recruiting --> Terminated; low enrollment, termination of funding
- ||||||| Mircera (methoxy polyethylene glycol-epoetin beta) / Roche, CSL Behring
Trial completion: A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia (clinicaltrials.gov) - Feb 22, 2014
P3, N=1228, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Terminated; low enrollment, termination of funding Active, not recruiting --> Completed
- | Epogen (epoetin alfa) / Amgen
Trial completion, HEOR: Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer (clinicaltrials.gov) - Feb 22, 2014
P3, N=282, Completed, Sponsor: Eastern Cooperative Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Epogen (epoetin alfa) / Amgen
Trial completion: Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome (clinicaltrials.gov) - Feb 22, 2014
P2, N=0, Completed, Sponsor: Fallon Clinic
Active, not recruiting --> Completed Suspended --> Completed
- | 5-fluorouracil / Generic mfg., cisplatin / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Metastases: Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=0, Completed, Sponsor: Eastern Cooperative Oncology Group
Suspended --> Completed Active, not recruiting --> Completed
- | Epogen (epoetin alfa) / Amgen
Trial completion: Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Northwestern University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Epogen (epoetin alfa) / Amgen
Trial completion, HEOR: Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy (clinicaltrials.gov) - Feb 19, 2014
P3, N=275, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Epogen (epoetin alfa) / Amgen
Enrollment closed: An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes (clinicaltrials.gov) - Feb 18, 2014
P3, N=132, Active, not recruiting, Sponsor: Janssen-Cilag International NV
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Musredo (molidustat) / Bayer
New P2 trial: DIALOGUE5: Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934 (clinicaltrials.gov) - Feb 13, 2014
P2, N=148, Recruiting, Sponsor: Bayer
- |||||||||| Evrenzo (roxadustat) / Astellas, AstraZeneca, FibroGen
New P3 trial: Himalayas: Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants (clinicaltrials.gov) - Jan 30, 2014
P3, N=750, Recruiting, Sponsor: FibroGen
- |||| Musredo (molidustat) / Bayer
Enrollment open: DIALOGUE4: Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934 (clinicaltrials.gov) - Nov 26, 2013
P2, N=148, Recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Epogen (epoetin alfa) / Amgen
Trial termination: Prevalence and Treatment of Anemia in Rehabilitation Patients (clinicaltrials.gov) - Nov 12, 2013
P4, N=22, Terminated, Sponsor: University of Medicine and Dentistry of New Jersey
Active, not recruiting --> Terminated; Study enrollment was suspended in response to an FDA alert regarding the study drug. The study was subsequently terminated
- Epogen (epoetin alfa) / Amgen, Venofer (iron sucrose complex) / Daiichi Sankyo
New P4 trial: The Effect of Epogen and Venofer Dosing Management on Hemoglobin Stability (clinicaltrials.gov) - Nov 3, 2013
P4, N=48, Terminated, Sponsor: Michael Germain
- ||||| Musredo (molidustat) / Bayer
New P2 trial: DIALOGUE4: Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934 (clinicaltrials.gov) - Nov 3, 2013
P2, N=148, Recruiting, Sponsor: Bayer
- Epogen (epoetin alfa) / Amgen
Enrollment closed: FRIEMAX: Efficacy Study of Epoetin Alfa in Friedreich Ataxia (clinicaltrials.gov) - Oct 27, 2013
P2, N=56, Active, not recruiting, Sponsor: Federico II University
The study was subsequently terminated Recruiting --> Active, not recruiting
- | Epogen (epoetin alfa) / Amgen
Combination therapy: NCI-2009-01173: Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia (clinicaltrials.gov) - Oct 6, 2013
P3, N=252, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Suspended --> Recruiting
- Epogen (epoetin alfa) / Amgen
Trial withdrawal: Procrit Versus Placebo to Determine Efficacy in Pre-Operative Major Surgical Oncology Operations (clinicaltrials.gov) - Sep 29, 2013
P2, N=0, Withdrawn, Sponsor: University of Louisville
Suspended --> Recruiting Completed --> Withdrawn
- Epogen (epoetin alfa) / Amgen
New P1/2 trial: Neonatal Erythropoietin And Therapeutic Hypothermia Outcomes in Newborn Brain Injury (NEATO) (clinicaltrials.gov) - Jul 30, 2013
P1/2, N=50, Recruiting, Sponsor: University of California, San Francisco
- | Farydak (panobinostat) / Secura Bio
Enrollment change, Combination therapy: GEPARD: LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS) (clinicaltrials.gov) - Jul 24, 2013
P4, N=33, Completed, Sponsor: Novartis Pharmaceuticals
Completed --> Withdrawn N=55 --> 33
- | Farydak (panobinostat) / Secura Bio
Trial completion, Combination therapy: GEPARD: LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS) (clinicaltrials.gov) - Jul 24, 2013
P4, N=33, Completed, Sponsor: Novartis Pharmaceuticals
N=55 --> 33 Recruiting --> Completed
- Epogen (epoetin alfa) / Amgen, Venofer (iron sucrose complex) / Daiichi Sankyo, CSL Behring
Enrollment open: The Benefits of a Preoperative Anemia Management Program (clinicaltrials.gov) - Jun 23, 2013
P=N/A, N=500, Recruiting, Sponsor: University of Alabama at Birmingham
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||||||| Epogen (epoetin alfa) / Amgen
Trial completion: A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS (clinicaltrials.gov) - Jun 23, 2013
P3, N=51, Completed, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Epogen (epoetin alfa) / Amgen
HEOR: Impact of Vitamin B12 Replacement on Epogen Dosing and Improvement of Quality of Life in Hemodialysis Patients (clinicaltrials.gov) - Jun 11, 2013
P=N/A, N=132, Completed, Sponsor: North Shore Long Island Jewish Health System
- | Eprex (epoetin alfa) / J&J, Epogen (epoetin alfa) / Amgen
Enrollment open: Erythropoietin in Traumatic Brain Injury (EPO-TBI) (clinicaltrials.gov) - May 11, 2013
P3, N=606, Recruiting, Sponsor: Australian and New Zealand Intensive Care Research Centre
Active, not recruiting --> Completed Ongoing --> Recruiting
- ||| Eprex (epoetin alfa) / J&J
Enrollment change: A Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin Alfa (clinicaltrials.gov) - Apr 14, 2013
P4, N=124, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Ongoing --> Recruiting N=750 --> 124
- Epogen (epoetin alfa) / Amgen
Trial termination: Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis (clinicaltrials.gov) - Mar 25, 2013
P4, N=41, Terminated, Sponsor: Amgen
N=750 --> 124 Recruiting --> Terminated; Terminated: Test article, Omontys, was recalled from the market; Enrollment has halted prematurely and will not resume; participants are no longer being treated
- Epogen (epoetin alfa) / Amgen
Enrollment change: Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis (clinicaltrials.gov) - Mar 25, 2013
P4, N=41, Terminated, Sponsor: Amgen
Recruiting --> Terminated; Terminated: Test article, Omontys, was recalled from the market; Enrollment has halted prematurely and will not resume; participants are no longer being treated N=225 --> 41
- ||||| Epogen (epoetin alfa) / Amgen, Omontys (peginesatide) / Affymax
Enrollment change: DIAMOND: Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis (clinicaltrials.gov) - Mar 7, 2013
P3, N=184, Completed, Sponsor: Affymax
N=225 --> 41 N=240 --> 184
- ||||||| Epogen (epoetin alfa) / Amgen, Omontys (peginesatide) / Affymax
Trial completion: DIAMOND: Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis (clinicaltrials.gov) - Mar 7, 2013
P3, N=184, Completed, Sponsor: Affymax
N=240 --> 184 Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Metastases: DREXNECK: Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer (clinicaltrials.gov) - Feb 19, 2013
P2, N=25, Recruiting, Sponsor: Drexel University
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- Epogen (epoetin alfa) / Amgen
Trial initiation date: Assess Functional Outcomes in Anemic, Critically Ill, Trauma Patients When Taking Epoetin Alfa (clinicaltrials.gov) - Feb 5, 2013
P2, N=192, Terminated, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Active, not recruiting --> Recruiting Initiation date: May 2005 --> Aug 2005
- |||| Evrenzo (roxadustat) / FibroGen
Trial completion: Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China (clinicaltrials.gov) - Jan 30, 2013
P2, N=96, Completed, Sponsor: FibroGen
Initiation date: May 2005 --> Aug 2005 Recruiting --> Completed
- Epogen (epoetin alfa) / Amgen
Trial initiation date: FRIEMAX: Efficacy Study of Epoetin Alfa in Friedreich Ataxia (clinicaltrials.gov) - Jan 6, 2013
P2, N=56, Active, not recruiting, Sponsor: Federico II University
Recruiting --> Completed Initiation date: Feb 2012 --> Jan 2013
- ||||| Epogen (epoetin alfa) / Amgen
Trial initiation date, Metastases: A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy (clinicaltrials.gov) - Dec 17, 2012
P3, N=2100, Recruiting, Sponsor: Janssen Research & Development, LLC
Initiation date: Feb 2012 --> Jan 2013 Initiation date: Nov 2005 --> Mar 2006
- Epogen (epoetin alfa) / Amgen
New P4 trial: Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis (clinicaltrials.gov) - Nov 28, 2012
P4, N=41, Terminated, Sponsor: Amgen
- Epogen (epoetin alfa) / Amgen
Trial completion: NEAT: Neonatal Erythropoietin in Asphyxiated Term Newborns (clinicaltrials.gov) - Nov 6, 2012
P1, N=24, Completed, Sponsor: University of California, San Francisco
Initiation date: Nov 2005 --> Mar 2006 Active, not recruiting --> Completed
- Epogen (epoetin alfa) / Amgen
Trial withdrawal, Metastases: Epoetin Alfa in Treating Fatigue in Patients With Advanced Solid Tumors Who Are Not Receiving Chemotherapy (clinicaltrials.gov) - Oct 17, 2012
P=N/A, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Completed --> Withdrawn
- Epogen (epoetin alfa) / Amgen
Enrollment change: Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer (clinicaltrials.gov) - Oct 2, 2012
P2, N=89, Completed, Sponsor: Jonsson Comprehensive Cancer Center
Completed --> Withdrawn N=180 --> 89
- Epogen (epoetin alfa) / Amgen
Trial completion: Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer (clinicaltrials.gov) - Oct 2, 2012
P2, N=89, Completed, Sponsor: Jonsson Comprehensive Cancer Center
N=180 --> 89 Active, not recruiting --> Completed
- Epogen (epoetin alfa) / Amgen
Enrollment change: Treating Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) With Epoetin Alfa (clinicaltrials.gov) - Sep 24, 2012
P4, N=3, Terminated, Sponsor: University of South Florida
Active, not recruiting --> Completed N=20 --> 3
- Epogen (epoetin alfa) / Amgen
Trial termination: Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Head and Neck Cancer (clinicaltrials.gov) - Sep 19, 2012
P3, N=47, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=20 --> 3 Active, not recruiting --> Terminated; low accrual
- Epogen (epoetin alfa) / Amgen, Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Enrollment change: Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer (clinicaltrials.gov) - Jun 17, 2012
P3, N=14, Completed, Sponsor: Jonsson Comprehensive Cancer Center
Active, not recruiting --> Terminated; low accrual N=200 --> 14